Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04176497 · ClinicalTrials.gov registry record · Phase 2
PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study
A Phase 2 study, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT04176497 is a Phase 2 study that was terminated before completion, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 8 participants.
The verdict
NCT04176497, a Phase 2 study, was terminated before completion, sponsored by UNC Lineberger Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The goal of this study is to investigate the feasibility and toxicity of using prostate-specific membrane antigen-positron emission tomography (PSMA-PET) and multi-parametric magnetic resonance imagining (mpMRI) with PET-MR technology to define radiotherapy targets, while meeting all the current planning criteria.
Interventions
- DRUG 68Ga-HBED-CC-PSMA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-07-16 |
| Est. Completion | 2024-10-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04176497
The ClinicalTrials.gov registry entry for NCT04176497 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 68Ga-HBED-CC-PSMA is the first listed.
NCT04176497 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04176497 about?
NCT04176497 is a clinical study titled "PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study". The goal of this study is to investigate the feasibility and toxicity of using prostate-specific membrane antigen-positron emission tomography (PSMA-PET) and multi-parametric magnetic resonance imagining (mpMRI) with PET-MR technology to define radiotherapy targets, while meeting all the current pla...
What is the current status of trial NCT04176497?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2020-07-16. Estimated completion is 2024-10-25.
What interventions are being tested in trial NCT04176497?
The interventions under investigation include: 68Ga-HBED-CC-PSMA (DRUG).
Who is sponsoring clinical trial NCT04176497?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.